Arrowstreet Capital
NBIX icon

Arrowstreet Capital’s Neurocrine Biosciences NBIX Stock Holding History

Arrowstreet Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.73M Buy
+28,051
New +$4.16M ﹤0.01% 1304
2026
Q1 		– Sell
-360,711
Closed -$51.2M – 2017
2025
Q4 		$51.2M Sell
360,711
-50,949
-12% -$7.38M 0.03% 475
2025
Q3 		$57.8M Buy
411,660
+286,498
+229% +$38.8M 0.04% 417
2025
Q2 		$15.7M Buy
125,162
+58,562
+88% +$6.72M 0.01% 765
2025
Q1 		$7.37M Buy
+66,600
New +$8.44M 0.01% 892
2024
Q4 		– Sell
-8,651
Closed -$997K – 1892
2024
Q3 		$997K Buy
8,651
+5,169
+148% +$709K ﹤0.01% 1388
2024
Q2 		$479K Sell
3,482
-27,281
-89% -$3.74M ﹤0.01% 1339
2024
Q1 		$4.24M Buy
+30,763
New +$4.2M ﹤0.01% 938
2023
Q3 		– Sell
-71,770
Closed -$6.77M – 1361
2023
Q2 		$6.77M Sell
71,770
-4,842
-6% -$473K 0.01% 578
2023
Q1 		$7.75M Buy
76,612
+12,386
+19% +$1.29M 0.01% 594
2022
Q4 		$7.67M Sell
64,226
-143,124
-69% -$16.8M 0.01% 583
2022
Q3 		$22M Buy
207,350
+100,361
+94% +$10.2M 0.03% 357
2022
Q2 		$10.4M Buy
106,989
+10,706
+11% +$988K 0.01% 488
2022
Q1 		$9.03M Sell
96,283
-16,099
-14% -$1.36M 0.01% 532
2021
Q4 		$9.57M Buy
+112,382
New +$10.3M 0.01% 664
2020
Q4 		– Sell
-12,900
Closed -$1.24M – 2452
2020
Q3 		$1.24M Buy
+12,900
New +$1.49M ﹤0.01% 1753
2018
Q4 		– Sell
-18,400
Closed -$2.26M – 1448
2018
Q3 		$2.26M Buy
+18,400
New +$2.09M 0.01% 664
2018
Q2 		– Sell
-18,600
Closed -$1.54M – 1233
2018
Q1 		$1.54M Buy
+18,600
New +$1.57M ﹤0.01% 789
2014
Q1 		– Sell
-60,409
Closed -$564K – 1263
2013
Q4 		$564K Sell
60,409
-42,881
-42% -$418K ﹤0.01% 948
2013
Q3 		$1.17M Buy
+103,290
New +$1.42M 0.01% 633

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital's NBIX Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 28,051 shares worth $4.73M. The stake represents ﹤0.01% of the portfolio and ranks #1304 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in NBIX as recently as Q4 2025.

Arrowstreet Capital first reported a position in NBIX in Q3 2013 and has held it in 20 quarters since. The position peaked at $57.8M in Q3 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Arrowstreet Capital held 28,051 shares of Neurocrine Biosciences worth $4.73M as of Q2 2026.
  • Neurocrine Biosciences was a new Arrowstreet Capital position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1304 holding.
  • Arrowstreet Capital first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 20 quarters since.
  • Arrowstreet Capital's Neurocrine Biosciences position peaked at $57.8M in Q3 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.